Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Actelion (ALIOF) recently announced positive results from a phase II study on its S1P1 modulator, ponesimod. Actelion is evaluating ponesimod as a treatment for patients suffering from moderate-to-severe chronic plaque psoriasis.

The study achieved its primary objective of improving at least 75% in Psoriasis Area and Severity Index (PASI) from baseline (PASI75) after 16 weeks. The study enrolled 326 patients. Results from the study showed that both doses of ponesimod (20 mg and 40 mg) achieved statistical significance.

Around 46% of patients treated with ponesimod (20 mg) showed an improvement of at least 75% in PASI, whereas 48.1% treated with ponesimod (40 mg) showed the same at the 16th week. Approximately 13% of patients under placebo showed an improvement of at least 75 % in PASI after the same duration of time.

Actelion now plans to initiate a phase III study on ponesimod in the psoriasis indication. Actelion will be discussing the phase III study details with health authorities around the world once full data analysis of the phase II results are done.

We remind investors that in July 2011, Actelion successfully completed a phase IIb dose-finding study with ponesimod for the treatment of patients suffering from multiple sclerosis.

We note already approved drugs for the treatment of moderate-to-severe plaque psoriasis include Johnson & Johnson’s (JNJ - Analyst Report) Stelara, Abbott Laboratories (ABT - Analyst Report) Humira and Pfizer Inc. (PFE - Analyst Report) and Amgen Inc.’s (AMGN - Analyst Report) Enbrel.

Actelion carries a Zacks #3 Rank (Hold) in the short run. Johnson & Johnson carries a Zacks #2 Rank (Buy) whereas Amgen carries a Zacks #1 Rank (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%